Publication: MAPPING THE CONTOURS OF THE EXPERIMENTAL USE EXEMPTION: 35 U.S.C. sect. 271(E)(1)'S PAST, PRESENT, AND FUTURE
Date
2000
Authors
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
MAPPING THE CONTOURS OF THE EXPERIMENTAL USE EXEMPTION: 35 U.S.C. sect. 271(E)(1)'S PAST, PRESENT, AND FUTURE (2000 Third Year Paper)
Research Data
Abstract
In 1984, Congress passed the Drug Price Competition and Patent Term Restoration Act (DPCPTR). This Act, which resulted from the lobbying efforts of both the pharmaceutical industry and consumer interest groups, was intended to encourage greater expenditure in the area of pharmaceutical invention while simultaneously ensuring greater competition immediately after the expiration of the relevant patents. "By rectifying distortions in the patent system created by the Food and Drug Administration's [FDA's] regulatory approval process, Congress struck a balance between the interests of pharmaceutical companies, competing 'generic' manufacturers," and consumers.
Description
Other Available Sources
Keywords
Food and Drug Law, patents, FDA, experimental, Drug Price Competition and Patent Term Restoration Act, veterinary products
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service